Contact the Editorial Desk

Editorial correspondence

Correspondence that improves the accuracy of the record is welcome: a citation quoted inaccurately, a regulatory reference that has changed, or a peer-reviewed publication on ipamorelin, CJC-1295, or sermorelin that should join the references page.

The most actionable notes carry three elements: the specific page they concern, the exact passage in question, and the corrective citation — a DOI or PubMed ID wherever possible. That combination lets a proposed change be verified against its source quickly.

Editorial mailbox: editors@peptidedivision.com

What this desk cannot do

So that messages don't pile up unanswered for the wrong reasons, several categories fall outside what this site can address.

Peptide Division sorts and reads the literature; it is not a clinic or a vendor. It cannot:

• Advise on, recommend, or comment on human use of any research compound covered here.
• Suggest a dose, schedule, or route of administration for any person.
• Diagnose any condition, or assess whether a particular research finding applies to any individual.
• Sell, source, recommend, or help locate any peptide from any supplier.
• Answer athletes under anti-doping rules about using these compounds, given that all three are prohibited under WADA S2.

Anyone with clinical or health questions should consult a licensed clinician in their own jurisdiction. Replies to editorial correspondence are not guaranteed and may be delayed; the mailbox is watched intermittently.